Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | PRKCA | P17252 | 1/20 | 0.35 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21120299 | 0.91 | KMT2A (0.42) | MEN1KMT2ASMN1; SMN2L3MBTL1ROCK2 | |
| SCHEMBL12157064 | 0.87 | KMT2A (0.43) | MEN1KMT2ASMN1; SMN2L3MBTL1ROCK2 | |
| SCHEMBL21480702 | 0.87 | KMT2A (0.39) | MEN1KMT2ASMN1; SMN2L3MBTL1ROCK2 | |
| SCHEMBL18792738 | 0.84 | MEN1 (0.42) | MEN1KMT2ASMN1; SMN2L3MBTL1ROCK2 | |
| SCHEMBL23318363 | 0.83 | KMT2A (0.41) | MEN1KMT2ASMN1; SMN2L3MBTL1ROCK2 | |
| SCHEMBL27305897 | 0.83 | ELANE (0.52) | MEN1KMT2ASMN1; SMN2L3MBTL1ELANE | |
| SCHEMBL18792766 | 0.82 | ELANE (0.46) | MEN1KMT2ASMN1; SMN2L3MBTL1ROCK2 | |
| SCHEMBL23051176 | 0.82 | ROCK2 (0.42) | MEN1KMT2ASMN1; SMN2L3MBTL1ROCK2 | |
| SCHEMBL24541057 | 0.81 | MEN1 (0.43) | MEN1KMT2ASMN1; SMN2L3MBTL1ROCK2 | |
| SCHEMBL23420957 | 0.81 | KMT2A (0.43) | MEN1KMT2ASMN1; SMN2L3MBTL1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795229-B2 | Methods of reducing side effects of anti-CD30 antibody drug conjugate therapy | SEATTLE GENETICS, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20230020999-A1 | ANTI-CD30 ANTIBODY-DRUG CONJUGATES AND THEIR USE FOR THE TREATMENT OF HIV INFECTION | RUBINSTEIN PAUL (US) | 2023-01-19 | — | — | US | disclosed |
| US-20210015939-A1 | METHODS OF TREATING CANCER WITH A COMBINATION OF A PLATINUM-BASED AGENT AND AN ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2021-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11795229-B2 | Methods of reducing side effects of anti-CD30 antibody drug conjugate therapy | CD2BP2, CD2, SIGLEC7 | MEN1 3334/4885KMT2A 1556/4885SMN1; SMN2 703/4885 |
| US-20230020999-A1 | ANTI-CD30 ANTIBODY-DRUG CONJUGATES AND THEIR USE FOR THE TREATMENT OF HIV INFECTION | CD4, CD2, CD81 | MEN1 4402/4885KMT2A 1032/4885SMN1; SMN2 4209/4885 |
| US-20210015939-A1 | METHODS OF TREATING CANCER WITH A COMBINATION OF A PLATINUM-BASED AGENT AND AN ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATE | F3, TFPI, ADAMTS13 | MEN1 1777/4885KMT2A 1811/4885SMN1; SMN2 4346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.